Stock Code: 002390 Stock Abbreviation: Xinbang Pharmaceutical Announcement No.: 2026-011 Guizhou Xinbang Pharmaceutical Co., Ltd. Announcement on Confirmation of Directors' and Senior Management's 2025 Remuneration and 2026 Remuneration Plan The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and contains no false records, misleading statements, or major omissions. Guizhou Xinbang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the Tenth Meeting of the Ninth Board of Directors on April 17, 2026, to review the remuneration plan for the Company's directors and senior management for 2025 and 2026. The details are as follows: I. Deliberation Procedures (I) "Proposal on Confirmation of Directors' 2025 Remuneration and 2026 Remuneration Plan"
- At the Fourth Meeting of the Ninth Board of Directors' Remuneration and Performance Appraisal Committee, all members abstained from voting on this proposal, and it was directly submitted to the Board of Directors for deliberation.
- At the Tenth Meeting of the Ninth Board of Directors, based on the principle of prudence, all directors abstained from voting on this proposal, and it was directly submitted to the Company's 2025 Shareholders' Meeting for deliberation.
- This proposal still needs to be submitted to the Company's 2025 Shareholders' Meeting for deliberation. (II) "Proposal on Confirmation of Senior Management's 2025 Remuneration and 2026 Remuneration Plan"
- At the Fourth Meeting of the Ninth Board of Directors' Remuneration and Performance Appraisal Committee, this proposal was deliberated and approved with 3 votes in favor, 0 votes against, and 0 abstentions.
- At the Tenth Meeting of the Ninth Board of Directors, this proposal was deliberated and approved by 7 non-related directors, with 0 votes against and 0 abstentions.
- This proposal does not require submission to the Shareholders' Meeting for deliberation. II. Remuneration Situation of Directors and Senior Management in 2025 In 2025, the Company issued allowances and remuneration to directors and senior management in accordance with the "Remuneration and Performance Appraisal Manageme